Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 1, 2006, Pages

  Tahseldar Roumieh, Rima ^a,b   Ghali Ghoul, Rana ^a   Lugnier, Claire ^b   Sabra, Ramzi ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b CNRS   (France)

Author keywords

Guanosine 3 ,5 cyclic monophosphate; Hemodynamics; Nitric oxide; Sodium retention; Vasodilation

Indexed keywords

[1,3 DIMETHYL 6 (2 PRPOXY 5 METHANESULFONYLAMIDOPHENYL)PYRAZOLO[3,4D] PYRIMIDIN 4 (5H) ONE; DIAZOXIDE; GLYCERYL TRINITRATE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE DONOR; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; PYRIMIDINONE DERIVATIVE; UNCLASSIFIED DRUG; 1,3 DIMETHYL 6 (2 PROPOXY 5 METHANESULFONYLAMIDOPHENYL)PYRAZOLO(3,4 D)PYRIMIDIN 4(5H) ONE; 1,3-DIMETHYL-6-(2-PROPOXY-5-METHANESULFONYLAMIDOPHENYL)PYRAZOLO(3,4-D)PYRIMIDIN-4(5H)-ONE; ALLOPURINOL; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; DRUG DERIVATIVE; PENICILLAMINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; S NITRO N ACETYLPENICILLAMINE; S-NITRO-N-ACETYLPENICILLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL PRESSURE; ARTICLE; BILE DUCT LIGATION; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; HEMODYNAMICS; KIDNEY FUNCTION; LIVER CIRRHOSIS; MUSCLE CONTRACTILITY; MUSCLE TONE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; SODIUM EXCRETION; VASCULAR RESISTANCE; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASODILATATION; ANIMAL; BILE DUCT; EXPERIMENTAL LIVER CIRRHOSIS; KIDNEY; KIDNEY FUNCTION TEST; LIGATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ALLOPURINOL; ANIMALS; BILE DUCTS; DIAZOXIDE; HEMODYNAMIC PROCESSES; KIDNEY; KIDNEY FUNCTION TESTS; LIGATION; LIVER CIRRHOSIS, EXPERIMENTAL; MUSCLE, SMOOTH, VASCULAR; NITROGLYCERIN; PENICILLAMINE; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 33644814421     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00507.2005     Document Type: Article

References (32)

1. Angeli P, Jimenex V, Veggian R, Fasolato S, Volpin R, MacHenzie HS, Craighera R, Dalla Libera V, Sticca A, Arroyo V, and Gatta A. Increased activity of guanosine 3′-5′-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology 31: 304-310, 2000.
2. + channels. Clin Sci (Lond) 99: 455-460, 2000.
3. Atucha NM, Shah V, Garcia-Cardena G, Sessa WE, and Groszmann RJ. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology 11: 1627-1632, 1996.
4. Cahill PA, Redmond EM, Hodges R, Zhang S, and Sitzmann JV. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 25: 370-378, 1996.
5. Colle I, De Vriese AS, Van Vlierberghe H, Lameire NH, and DeVos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int 24: 63-68, 2004.
6. Colle IO, De Vriese AS, Van Vlierberghe HR, Lameire NH, and De Vos MM. Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study. Eur J Gastroenterol Hepatol 16: 139-145, 2004.
7. Coste H and Grondin P. Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem Pharmacol 50: 1577-1585, 1995.
8. Deka DK, Raviprakash V, and Mishra SK. Basal nitric oxide release differentially modulates vasodilations by pinacidil and levcromakalim in goat coronary artery. Eur J Pharmacol 348: 11-23, 1998.
9. Delpy E and le Monnier de Gouville A-C. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMMPO: in vitro and in vivo characterization. Br J Pharmacol 118: 1277-1284, 1996.
10. Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, Gupta T, and Groszmann RJ. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology 36: 381-385, 2000.
11. ω-nitro-L-arginine methyl ester-sensitive responses to cromakalim and diazoxide in the rat mesenteric bed. Eur J Pharmacol 319: 229-238, 1997.
12. Fernandez M, Garcia-Pagan JC, Casadevall M, Bernadich C, Piera C, Whittle BJR, Piqué JM, Bosch J, and Rodés J. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology 108: 1487-1495, 1995.
13. Iwakiri Y, Cadelina G, Sessa WC, and Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 283: G1074-G1081, 2002.
14. Kagota S, Yamaguchi Y, Nakamura K, Shinozuka K, and Kunitomo M. Sustaining excessive nitric oxide upregulates protein expression of nitric oxide synthase via soluble guanylyl cyclase: an in vivo study in rats. J Cardiovasc Pharmacol 44: 42-49, 2004.
15. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, and Yan C. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104: 2338-2343, 2001.
16. Lee SS, Pak JM, Medlicott SM, and Bomzon A. Vasodilatory responses of isolated arteries of cirrhotic rats. Clin Sci (Lond) 89: 227-232, 1995.
17. Lugnier C, Schoeffter P, Le Bec A, Strouthou E, and Stoclet JC. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35: 1743-1751, 1986.
18. Lugnier C and Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J 14, Suppl I: 141-148, 1993.
19. McCulloch AI and Randall MD. Modulation of vasorelaxant responses to potassium channel openers by basal nitric oxide in the rat isolated superior mesenteric arterial bed. Br J Pharmacol 117: 859-866, 1996.
20. Ni X, Cheng Y, Cao L, Gardner DG, and Humphreys MH. Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile duct ligations. J Am Soc Nephrol 72: 2110-2118, 1996.
21. Ni XP, Safai M, Gardner DG, and Humpreys MH. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation. Kidney Int 59: 1264-1273, 2001.
22. Niederberger M, Gines P, Martin PY, Tsai P, Morris K, McMurtry I, and Schrier RW. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 24: 947-951, 1996.
23. Ortiz MC, Fortepiani LA, Martinez C, Atucha NM, and Garcia-Estan J. Vascular hyporesponsiveness in aortic rings from cirrhotic rats: role of nitric oxide and endothelium. Clin Sci (Lond) 91: 733-738, 1996.
24. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, and Beavo JA. PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22: 469-78, 2003.
25. Rybalkin SD, Yan C, Bornfeldt KE, and Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280-291, 2003.
26. Schreier RW, Arroyo V, Bernardi M, Epstein M, Henrikson JH, and Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151-1157, 1988.
27. Sogni P, Moreau R, Ohsuga M, Cailmail S, Oberti F, Hadengue A, Pussard E, and Lebrec D. Evidence for normal nitric oxide-mediated vasodilator tone in conscious rats with cirrhosis. Hepatology 16: 980-983, 1992.
28. Thiesson HC, Jensen BL, Jespersen B, Schaffalitzky de Muckadell OB, Bistrup C, Walter S, Ottosen PD, Veje A, and Skott O. Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol 288: F1044-F1052, 2005.
29. Van Obbergh L, Leonard V, Chen H, Xu D, and Blaise G. The endothelial and non-endothelial mechanism responsible for attenuated vasoconstriction in cirrhotic rats. Exp Physiol 80: 609-617, 1995.
30. Warner L, Skorecki K, Blendis LM, and Epstein M. Atrial natriuretic factor and liver disease. Hepatology 17: 500-513, 2003.
31. Wensing G and Branch RA. Phenobarbital influences the development of sodium retention in liver disease induced by bile duct ligation in the rat. Hepatology 11: 773-778, 1990.
32. Wiest R and Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35: 78-91, 2002.